Taxanes in the management of gynecologic malignancies

Expert Review of Anticancer Therapy

Volumn 8, Issue 2, 2008, Pages 219-226

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cervical cancer; Docetaxel; Endometrial cancer; Ovarian cancer; Paclitaxel; Taxanes

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG UTILIZATION; ENDOMETRIUM CANCER; FEMALE; GERM CELL TUMOR; GRANULOSA CELL TUMOR; GYNECOLOGIC CANCER; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MIXED MULLERIAN TUMOR; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPTIMAL DRUG DOSE; OVARY CANCER; PERIPHERAL NEUROPATHY; RECURRENT CANCER; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERUS CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 40749125593     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.2.219     Document Type: Review

References (89)

1. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N. Engl. J. Med. 332, 1004-1014 (1995).
2. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82, 1247-1259 (1990).
3. Kris MG, O'Connell JP, Gralla RJ et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat. Rep. 70, 605-607 (1986).
4. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettihber DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat. Rep. 71, 1171-1177 (1987).
5. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111, 273-279 (1989).
6. Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8, 1263-1268 (1990).
7. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12, 1748-1753 (1994).
8. Einzig AI, Wiernik PH, Sasloff J et al. Phase II study and long term follow-up of patients treated with taxol for advanced ovarian cancer adenocarcinoma. J. Clin. Oncol. 10, 1748-1753 (1992).
9. Aravantinos G, Skarlos DV, Kosmidis P et al. A Phase II study of paclitaxel in platinum pretreated ovarian cancer: a Hellenic Cooperative Oncology Group study. Eur. J. Cancer 33, 160-163 (1997).
10. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12, 2654-2666 (1994).
11. Trimble EL, Adams JD, Vina D et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 11, 2405-2410 (1993).
12. McGuire WP, Hoskins WJ, Brady WF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6 (1996).
13. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian caner: three-year results. J. Natl Cancer Inst. 92, 699-708 (2000).
14. Piccart MJ, Bertelsen K, Stuart G et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int. J. Gynecol. Cancer 13(Suppl. 2), 144-148 (2003).
15. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON-3 randomized trial. Lancet 360, 505-515 (2002).
16. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 18, 106-115 (2000).
17. Neijt JP, Engelholm SA,Tuxen MK et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18, 3084-3092 (2000).
18. Ozols RF, Bundy BN, Greer BE et al. Phase III study of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194-3200 (2003).
19. duBois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95, 1320-1329 (2003).
20. Covens A, Carey M, Bryson P et al. Systemic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol. Oncol. 85, 71-80 (2002).
21. Connelly E, Markman M, Kennedy A et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol. Oncol. 62, 166-168 (1996).
22. Cortes JE, Pazdur R. Docetaxel. J. Clin. Oncol. 13, 2643-2655 (1995).
23. Francis P, Schneider J, Hann L et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. Clin. Oncol. 12, 2301-2308 (1994).
24. Piccart MJ, Gore M, ten Bokkel Huinink W et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J. Natl. Cancer Inst. 87, 676-681 (1995).
25. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere®) in advanced ovarian cancer: an updated overview. Eur. J. Cancer 33, 2167-2170 (1997).
26. Verschraegen CF, Sittisomwong T, Kudelka AP et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J. Clin. Oncol. 18, 2733-2739 (2000).
27. Rose PG, Blessing JA, Ball HG et al. A Phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88, 130-135 (2003).
28. Vasey PA, Paul J, Birt A. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J. Clin. Oncol. 17, 2069-2080 (1999).
29. Vasey PA, Atkinson R, Coleman R et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br. J. Cancer 84, 170-178 (2001).
30. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96, 1682-1691 (2004).
31. Markman M, Kennedy A, Webster K et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J. Clin. Oncol. 19, 1901-1905 (2001).
32. Omura GA, Brady MF, Look KY et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an Intergroup study. J. Clin. Oncol. 21, 2843-2848 (2003).
33. Spriggs DR, Brady MF, Rubin S et al. A Phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG 162). J. Clin. Oncol. 25, 4466-4471 (2007).
34. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16, 1494-1497 (1998).
35. Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83, 128-134 (2001).
36. Dixon DS, Hensley ML, Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J. Clin. Oncol. 20, 1238-1247 (2002).
37. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361, 2099-2106 (2003).
38. Fennelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15, 187-192 (1997).
39. Kita T, Kikuchi Y, Takano M et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol. Oncol. 92, 813-818 (2004).
40. Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 20, 2365-2369 (2002).
41. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol. 101, 436-440 (2006).
42. Hainsworth JD, Burris HA III, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. J Clin. Oncol. 19, 3500-3505 (2001).
43. Lilenbaum RC, Schwartz MA, Seigel L et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 92, 2158-2163 (2001).
44. Komiyama S, Mizusawa Y, Onouchi M et al. Effective weekly docetaxel for recurrent ovarian cancer: a case report. Int. J. Gynecol. Cancer 13, 683-686 (2003).
45. Markman M, Hakes T, Barakat R et al. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center Protocol 9103: paclitaxel in refractory ovarian cancer. J. Clin. Oncol. 14, 796-799 (1996).
46. Rohl J, Kushner D, Markman M. Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol. Oncol. 81, 201-205 (2001).
47. Von Gruenigen VE, Karlen JR, Waggoner SE. A case of chronic paclitaxel administration in ovarian cancer. Gynecol. Oncol. 89, 532-535 (2003).
48. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21, 2460-2465 (2003).
49. Markman M, Liu P, Wilczynski S et al. Survival of ovarian cancer patients treated on SWOG 9701/GOG 178:12 versus 3 cycles of monthly single-agent paclitaxel following attainment of a clinically-defined complete response to platinum/paclitaxel. J. Clin. Oncol. 24(Suppl. 18), S257 (2006) (Abstract 5005).
50. Conte PF, Favalli G, Gadducci A et al. Final results of After-6 protocol: a Phase III trial of observation versus 6 courses of paclitaxel in advanced ovarian cancer patients in complete response after platinum-paclitaxel chemotherapy. J. Clin. Oncol. 25(Suppl. 18), S275 (2007) (Abstract 5505).
51. Markman M, Rowinsky E, Hakes T et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J. Clin. Oncol. 10, 1485-1491 (1992).
52. Francis P, Rowinsky E, Schneider J et al. Phase I feasibility and pharmacokinetic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J. Clin. Oncol. 13, 2961-2967 (1995).
53. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J. Clin. Oncol. 16, 2620-2624 (1998).
54. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43 (2006).
55. Teneriello MG, Tseng PC, Crozier M et al. Results of a Phase II evaluation of nanoparticle albumin bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J. Clin. Oncol. 25(Suppl. 18), S280 (2007) (Abstract, 5525).
56. Sabbatini P, Aghajanian C, Dizon D et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 22, 4523-4531 (2004).
57. Ball HG, Blessing JA, Lentz SS, Mutch DG. A Phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 62, 278-281 (1996).
58. Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88, 277-281 (2003).
59. Woo HL, Swenetton KD, Hoskins PJ. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J. Clin. Oncol. 19, 290-291 (1996).
60. Lissoni A, Zanetta G, Losa G et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann. Oncol. 7, 861-863 (1996).
61. Fleming GF. Fowler JM, Waggoner SE et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: A Gynecologic Oncology Group study. J. Clin. Oncol. 19, 1021-1029 (2001).
62. Fleming GE Bruneto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22, 2159-2166 (2004).
63. Hoskins PJ, Swenerton KD, Pike JA et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer a Phase II study. J Clin. Oncol. 19, 4048-4053 (2001).
64. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynerol. Oncol. 74, 272-277 (1999).
65. Sovak MA, Dupont J, Hensley ML et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int. J. Gynecol. Cancer 17, 197-203 (2007).
66. Michener CM, Peterson G, Kulp B, Webster KD, Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J. Cancer Res. Clin. Oncol. 131, 581-584 (2005).
67. Katsumata N, Noda K, Nozawa S et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer. a Japanese Cooperative Study. Br. J. Cancer 93, 999-1004 (2005).
68. Gunthert AR, Ackermann S, Beckmann MW et al. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer AGO Uterus-4. Gynecol. Oncol. 104, 86-90 (2007).
69. Vermorken JB. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review. Int. J. Gynecol. Cancer 3, 129-142 (1993).
70. Green JA, Kirwan JM, Tierney JF et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systemic review and meta-analysis. Lancet 358, 781-786 (2001).
71. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. a Gynecologic Oncology Group study. J. Clin. Oncol. 14, 792-795 (1996).
72. Curtin JP, Blessing JA, Webster KD et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 19, 1275-1278 (2001).
73. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 17, 2676-2680 (1999).
74. Papadimitriou CA,Sarris K,Lia A et al. Phase II trial of Paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J. Clin. Oncol. 17, 761-766 (1999).
75. Piver MS, Ghamande SA, Eltabbakh GH, O'Neill-Coppola C. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix: a Phase II study. Gynecol. Oncol. 75, 334-337 (1999).
76. Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 22, 3113-3119 (2004).
77. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J. Clin. Oncol. 21, 1180-1189 (2003).
78. Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. J. Clin. Oncol. 25, 2944-2951 (2007)
79. Tresukosol D, Kudelka AP, Edwards CL et al. Recurrent ovarian granulosa cell tumor: a case report of a dramatic response to taxol. Int. J. Gynecol. Oncol. 5, 156-159 (1995).
80. Brown J, Shvartsman HS, Deavers MT et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J. Clin. Oncol. 22, 3517-3523 (2004).
81. Brown J, Slivartsman HS, Deavers MT et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol. Oncol. 97, 489-496 (2005).
82. Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in die treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 83, 268-270 (2001).
83. Homesley HD, Filiaci V, Markman M et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 25, 526-531 (2007).
84. Toyoshima M, Akahira J, Matsunaga G et al. Cinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosamoma of the uterus. Gynecol. Oncol. 94, 774-778 (2004).
85. Duska LR, Garrett A, Eltabbakh GH et al. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol. Oncol. 85, 459-463 (2002).
86. Hinton S, Catalono P, Einhorn LH et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 20, 1859-1863 (2002).
87. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J. Clin. Oncol. 25, 513-516 (2007).
88. Motzer RJ,Mazumdar M,Sheinfeld J et al. Sequential close-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J. Clin. Oncol. 18, 1173-1180 (2000).
89. Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J. Clin. Oncol. 19, 81-88 (2001).